contact profile privacysearch log in
HomeAbout Us Board of Directors

Board of Directors
2019 - 2020

Officers

  • President

    Michael S. Cookson, MD, MMHC, FACS Show More
    University of Oklahoma
    Health Sciences Center-Dept. of Urology
    920 Stanton L. Young Blvd.
    WP 2140
    Oklahoma City, OK 73104
    Michael S. Cookson, MD

    Michael S. Cookson, MD is Professor and Chairman of the Department of Urology at the University of Oklahoma Health Sciences Center, and holds the Donald D. Albers Endowed Chair in Urology. An accomplished researcher and lecturer, he is the author of 206 peer-reviewed journal publications and 28 chapters of various textbooks in urology and urologic surgery, and has been recognized nationally for his outstanding contributions to urologic oncology.

    Dr. Cookson completed his Urology residency at the University of Texas, San Antonio and completed his Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York. He was a member of the faculty at Vanderbilt University from 1998 to 2013, where he served as the Vice Chairman of Urologic Surgery and Director of the Urologic Oncology Fellowship Program.

    Dr. Cookson has devoted a significant portion of his academic career to the management of patients with urologic cancers, with a strong emphasis on Clinical Guidelines, Education and Evidenced Based Medicine. He was a member of the AUA/ABU examination committee for 10 years, including a member of Task for Cancer, Oncology Consultant and Pathology editor. He also serves on the ABU Oral Examination Committee. He is a co-founder of the OKAT, an SUO mandated oncology examination that is the standard for benchmarking for members and oncology fellows in training and served as Chair of that OKAT committee for 5 years. In 2011, he received the President’s Distinguished Service Award from the SUO for educational contributions. For his efforts in teaching at Vanderbilt, he was awarded the Michael Rodriquez Award.

    Dr. Cookson recently served as the Chair of the AUA Guidelines Committee on Castration Resistant Prostate Cancer, and has previously served as the member of the AUA Guidelines on localized prostate cancer. He currently serves as Treasurer for the Society of Urologic Oncology.
  • President-Elect

    Jeffrey Maxwell Holzbeierlein, MD, FACS Show More
    University of Kansas Medical Center
    4000 Cambridge St
    MS-3016
    Kansas City, KS 66160
    Jeffrey Holzbeierlein, MD

    Dr. Jeffrey Holzbeierlein is the John W. Weigel Endowed Professor of Urology and the Director of Urologic Oncology at the University of Kansas Medical Center. He was raised in Edmond, Oklahoma and received his undergraduate degree from Vanderbilt University where he played for the men’s tennis team. He received his medical degree from the University of Oklahoma and joined the faculty at KU after completing his internship and residency at Vanderbilt University and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York.

    Dr. Holzbeierlein is a member of the Society of Urologic Oncology where he is the past Chair of the Fellowship Committee and serves on the Executive Board of the SUO. He is the President-Elect of the South Central Section of the American Urological Association and serves on the Board of Directors. He has served on the American Board of Urology Examination Committee and is currently and Oral Examiner for the Board Exams. He is a past Assistant Editor for the Journal of Urology. Dr. Holzbeierein has served on numerous AUA Committees including: the Practice Guidelines Committee and the Public Media Committee and has completed the AUA Leadership Program. In addition, he is a Fellow of the American College of Surgeons and serves on the Kansas selection board. Dr. Holzbeierlein is also the past Chair and founding member of the Young Urologic Oncologists Section of the Society of Urologic Oncology. He is a reviewer for the Journal of Urology, Practical Reviews in Urology, Cancer, and Urologic Oncology. He was recently awarded the Resident Mentoring Award for faculty at the University of Kansas Hospital.

    Dr. Holzbeierlein serves on numerous hospital committees including the University of Kansas Physicians Board of Directors, the Promotions and Tenure Committee, the Elections Committee for the School of Medicine, and the Board for the Kansas Tissue and Serum Repository. He is also co-director of the K-Inbre Translational Research Core, and the Director of the Genitourinary Disease Working Group. He is the Director of the Burns and McDonnell High Risk Prostate Cancer Prevention and Survivorship Clinic at the University of Kansas Cancer Center.

    Dr. Holzbeierlein has published numerous peer reviewed journal articles, and has numerous presentation and abstracts in journals and textbooks dealing with urologic oncology. He has been an annual lecturer for an AUA Course focusing on the Management of High Risk Superficial Bladder Cancer which was selected as one of the “best courses” at the AUA. He has intramural and extramural grant support including a co-investigator on an R01, and as PI on several investigator initiated trials and Pharma trials.

    Dr. Holzbeierlein specializes in the treatment of genitourinary malignancies including prostate, bladder, kidney, testicular, and penile cancers. His research interest includes the androgen receptor as a target of Hsp90 inhibitors in prostate cancer and clinically decreasing the morbidity associated with cystectomy. He lives in Kansas City with his wife Jill and their 4 children, and is civically active at the Hope Lodge of Kansas City and Maisson deNaissance.
  • Secretary

    Adam Stuart Kibel, MD Show More
    Brigham and Women's Hospital
    45 Francis Street
    Boston, MA 02115
  • Treasurer

    Daniel W. Lin, MD Show More
    University of Washington
    Department of Urology
    1959 NE Pacific, BB1106 B
    Campus Box 356510
    Seattle, WA 98195
  • Past President

    Christopher Paul Evans, MD, FACS Show More
    University of California, Davis
    Department of Urologic Surgery
    4860 Y Street
    Suite 3500
    Sacramento, CA 95817
    Christopher P. Evans, M.D., F.A.C.S.

    Dr. Evans is professor and chairman of the Department of Urologic Surgery at University of California, Davis School of Medicine and a member of the UC Davis Cancer Center. Dr. Evans attended Dartmouth Medical School on a Health Professional Services Program scholarship and he served on active duty in the United States Army, including two years as Chief of Experimental Surgery at the Walter Reed Army Institute of Research.

    Dr. Evans completed surgery and urology training at the University of California, San Francisco where he was also a National Kidney Foundation Scholar. He completed fellowship training in urologic oncology at the University of Texas, M.D. Anderson Cancer Center. He came to UC Davis in 1997 at which time he was also Director of Urology Research. In 2006, Dr. Evans became Department Chairman. In 2010, he became Chairman of the UC Davis Medical Group Practice Management Board.

    Dr. Evans’ practice is dedicated to the management of patients with urologic malignancies. Dr. Evans’ research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor and mediate drug-resistance. His laboratory work has tested new agents and brought them from bench studies to animal models to clinical trials.

    Dr. Evans is a Past Chair of the ASCO-GU Steering Committee and an elected member of the American Association of Genitourinary Surgeons. His research laboratory has received funding from the National Institutes of Health, Department Of Defense, New York Academy of Medicine, Prostate Cancer Foundation, Stand-Up To Cancer and the American Cancer Society. He has published over 180 peer-reviewed articles.

  • Member at Large

    Stephen Anthony Boorjian, MD Show More
    Mayo Clinic Rochester
    200 1st St. SW
    Rochester, MN 55905
    Stephen Anthony Boorjian, MD

    Dr. Stephen A. Boorjian is a Professor of Urology, Vice Chair of Research for the Department of Urology, and the Director of the Urologic Oncology Fellowship at Mayo Clinic. He received his MD from Harvard Medical School, and was a resident in Urology at New York Presbyterian Hospital-Weill Cornell Medical Center. He subsequently completed a fellowship in Urologic Oncology at Mayo Clinic. His research interests include optimizing the management for patients with high-risk prostate cancer, evaluating the outcomes among patients undergoing radical cystectomy for bladder cancer, and improving surgical therapy for advanced renal cell carcinoma. Dr. Boorjian has co-authored over 200 manuscripts and book chapters, and was recognized as “Teacher of the Year” in Urology for 2012 by the Mayo Clinic Fellows’ Association. He is a member of the NCCN Guidelines Panels for Bladder Cancer and Penile Cancer, and serves an Associate Editor for European Urology.
  • Member at Large

    Badrinath R. Konety, MD, MBA Show More
    University of Minnesota
    420 Delaware St. SE
    MMC 394 RM B535
    Minneapolis, MN 55455
  • Member at Large

    Badar Munir Mian, MD Show More
    Albany Medical Center
    23 Hackett Blvd
    Albany, NY 12208-3436
  • Winter Scientific Program Co-Chairs

    Peter Earl Clark, MD Show More
    Atrium Health, Levine Cancer Institute
    1021 Morehead Medical Drive
    Suite 6100
    Charlotte, NC 28204
    Peter Earl Clark, MD

    Dr. Clark completed his urologic residency at the Cleveland Clinic Foundation and subsequently did his urologic oncology fellowship training at the University of Southern California. He is currently a Professor of Urologic Surgery at Vanderbilt University Medical Center in Nashville TN, where he is also the Residency Program Director. Dr. Clark has an active clinical practice focused primarily on bladder and kidney cancer as well as an active basic science laboratory studying the role of MAPK’s and canonical Wnt signaling on kidney and bladder oncogenesis. He currently is Chair of the bladder cancer guidelines panel for the National Comprehensive Cancer Network (NCCN) and is a member of non-muscle invasive bladder cancer and small renal mass guidelines panels for the American Urologic Association (AUA). He is serving as the representative for the Southeast Section of the AUA to the Office of Research, Judicial and Ethics Committee, and the Practice Guidelines Committee. He is on the editorial board for several journals including the Journal of Urology, BJUI, Urologic Oncology, PCAN, and UROLOGY. He is an active member of both the Society of Urologic Oncology for which he is Chair of the SUO Fellowship Committee and the Society of Basic Urologic Research for which he serves on the Executive Board. He has over 145 publications in both the clinical and basic sciences.
  • Winter Scientific Program Co-Chairs

    Edward M. Schaeffer, MD, PhD Show More
    Northwestern University Feinberg School of Medicine
    676 N. St. Clair
    Arkes Family Pavilion, Ste 23-013
    Chicago, IL 60611
  • Young Urologic Oncologists Representative

    Brian F. Chapin, MD Show More
    MD Anderson Cancer Center
    Dept. of Urology
    1515 Holcombe Blvd.
    Unit 1373
    Houston, TX 77030
  • Young Urologic Oncologists Representative

    Sarah P. Psutka, MD, MSc Show More
    University of Washington
    1959 NE Pacific Street
    Box 356158
    Seattle, WA 98195
    https://www.uwmedicine.org/bios/sarah-psutka
  • Spring Scientific Program Co-Chairs

    John L. Gore, MD, MS Show More
    University of Washington Medical Center
    1959 NE Pacific St., Box 356510
    Seattle, WA 98195-6510
  • Spring Scientific Program Co-Chairs

    Surena F. Matin, MD Show More
    MD Anderson Cancer Center
    Department of Urology
    1515 Holcombe Blvd
    Unit 1373
    Houston, TX 77030
    Surena F. Matin, MD, FACS

    Primary Appointment
    Monteleone Family Foundation Distinguished Professor with Tenure, Department of Urology; Medical Director, Minimally Invasive New Technology in Oncologic Surgery (MINTOS) multidisciplinary program; University of Texas MD Anderson Cancer Center, Houston, Texas.

    Bio Statement
    Dr. Matin attended Old Dominion University on a 4-year scholarship and graduated Summa Cum Laude in Biology with a minor in English. After completing his medical education at Cornell University Medical College in New York City, he served a one year internship and 5 year residency at the Cleveland Clinic Foundation. He then completed a one year research fellowship in tumor immunology funded by a scholarship from the American Foundation for Urologic Disease (AFUD) in the laboratory of James Finke, PhD. He spent another year as a clinical fellow in Endourology and Minimally Invasive Surgery under the mentorship of Drs. Andrew Novick, Stevan Streem, and Inderbir Gill. Dr. Matin is board-certified in Urology, a Fellow of the American College of Surgeons, and served on the Board of Directors of the Society of Urologic Oncology from 2012-2015, for which he was co-chair of the SUO Winter Program for those 3 years. Dr. Matin has an active clinical practice specializing in the minimally invasive treatment of genitourinary cancers, including the entire spectrum of renal cell carcinoma (RCC), upper urinary tract urothelial cancer (UTUC), and prostate cancer. Specific areas of interest include improving clinical risk stratification, neoadjuvant, endourologic, and surgical approaches to UTUC, RPLND for UTUC, adjuvant therapies for RCC, minimally invasive and non-invasive therapies for kidney tumors, robotic surgery, and microlaparoscopic approaches for adrenal tumors. His primary research interest focuses on improving clinical outcomes and understanding the biology of UTUC, while his clinical research spectrum touches on the optimal integration of minimally invasive interventions within the entire spectrum of oncologic care. Dr. Matin was appointed Medical Director of the Minimally Invasive New Technology in Oncologic Surgery Collaborative Program at MD Anderson Cancer Center in 2007, a position interacting with all surgical departments delivering clinical administrative services, interdisciplinary educational venues and Perioperative Telemedicine™ research endeavors.

Standing Committee Chairs

  • Awards Committee Chair

    Christopher Paul Evans, MD, FACS Show More
    University of California, Davis
    Department of Urologic Surgery
    4860 Y Street
    Suite 3500
    Sacramento, CA 95817
    Christopher P. Evans, M.D., F.A.C.S.

    Dr. Evans is professor and chairman of the Department of Urologic Surgery at University of California, Davis School of Medicine and a member of the UC Davis Cancer Center. Dr. Evans attended Dartmouth Medical School on a Health Professional Services Program scholarship and he served on active duty in the United States Army, including two years as Chief of Experimental Surgery at the Walter Reed Army Institute of Research.

    Dr. Evans completed surgery and urology training at the University of California, San Francisco where he was also a National Kidney Foundation Scholar. He completed fellowship training in urologic oncology at the University of Texas, M.D. Anderson Cancer Center. He came to UC Davis in 1997 at which time he was also Director of Urology Research. In 2006, Dr. Evans became Department Chairman. In 2010, he became Chairman of the UC Davis Medical Group Practice Management Board.

    Dr. Evans’ practice is dedicated to the management of patients with urologic malignancies. Dr. Evans’ research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor and mediate drug-resistance. His laboratory work has tested new agents and brought them from bench studies to animal models to clinical trials.

    Dr. Evans is a Past Chair of the ASCO-GU Steering Committee and an elected member of the American Association of Genitourinary Surgeons. His research laboratory has received funding from the National Institutes of Health, Department Of Defense, New York Academy of Medicine, Prostate Cancer Foundation, Stand-Up To Cancer and the American Cancer Society. He has published over 180 peer-reviewed articles.
  • Bylaws Committee Chair

    Robert Guy Uzzo, MD Show More
    Temple Fox Chase Cancer Center
    Department of Surgery
    333 Cottman Ave. RM. C302
    Philadelphia, PA 19111
  • Clinical Trials Committee

    Gennady Bratslavsky, MD Show More
    SUNY Upstate Urology
    750 E Adams St
    Syracuse, NY 13210-2306
  • Education Committee Chair